Prothena Corporation plc (PRTA) NASDAQ
9.19
-0.4(-4.17%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Prothena Corporation plc
Address
77 Sir John Rogerson’s Quay
Dublin, 2
United States of America (the)
Phone
353 1 236 2500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
163
First IPO Date
December 18, 2012
Key Executives
| Name | Title | Pay | Year Born |
| Gene G. Kinney | President, Chief Executive Officer & Director | 1.12M | 1969 |
| Michael J. Malecek | Chief Legal Officer & Company Secretary | 588,250 | 1966 |
| Wagner Zago | Chief Scientific Officer | 735,660 | 1973 |
| Chad Swanson | Chief Development Officer | 739,084 | N/A |
| Brandon S. Smith | Chief Operating Officer | 826,819 | 1975 |
| Tran Nguyen | Chief Financial Officer | 916,334 | 1974 |
| Mark C. Johnson | Vice President of Investor Relations | 0 | N/A |
| Annie Evans Kingston | Chief Strategy Officer | 0 | N/A |
| Karin L. Walker | Chief Accounting Officer & Controller | 0 | 1963 |
| Phillip Dolan | Sr. Director & Head of Exploratory Research | 0 | N/A |
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
